Moderna stock jumps after melanoma vaccine with Merck meets key goals in large trial
AI Market Summary
Moderna's personalized mRNA melanoma vaccine with Merck's Keytruda met primary and secondary interim endpoints in a 1,137-patient Phase 3 trial, with no new safety signals reported. The readthrough supports Moderna's post-COVID pipeline diversification and improves visibility for a potentially meaningful oncology revenue stream (Barclays estimates ~$3B by 2035). The news is supportive for Moderna and, to a lesser extent, Merck risk sentiment.
Impact level
● Medium
Affected assets
NCSKMRNA2USD/USDT+4.65%
AI Insight · NCSKMRNA2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Moderna and Merck said their jointly developed melanoma vaccine succeeded in a large trial enrolling 1,137 high-risk post-surgery patients. Earlier mid-stage data showed the therapy cut the five-year risk of recurrence or death by 49%. Barclays analysts have said they expect the treatment could generate about $3 billion in melanoma sales by 2035. Moderna shares surged in premarket trading, while Merck rose 7.5%.
